



"CAPTURING CANCER COMPLEXITY AND CLINICAL CHALLENGES"

CCBIO1 Newsletter

DIRECTOR'S COMMENTS

EDITOR: eli.vidhammer@uib.no

Dear all

It has been a very active term and I would like to thank you all for your efforts. In particular, the CCBIO Annual Symposium in May became a success! Being online for the first time, we managed to attract 330 participants representing a truly international audience. Top notch presentations and engaged discussions. The speed presentations turned out to be an excellent format and will be repeated! Thank you all for helping out in various ways.

Congratulations to many of you: Dana Costea for receiving the Pindborg Award, Ole Frithjof Norheim for receiving the Dissemination Award at the Medical Faculty, and to Emmet McCormack for receiving the UIB-IDÉ grant. Also congratulations to Emmet McCormack and Camilla Krakstad for receiving grants from NFR (RCN), and to Katrin Kleinmanns for being appointed as the very first Mentee of ESMI's (European Society for Molecular Imaging) Mentoring Program "Advancing Careers of Early-Stage Imaging Scientists in Academia".

As usual, I would ask you to pay close attention to our calendar since there are many upcoming courses and events to be noted. In particular, three joint courses between CCBIO and Neuro-SysMed will take place this fall. The deadline for registration to UIB courses is September 1.

Let me also remind you that this year's SCANPATH Conference for pathology based tissue research, initiated by CCBIO in 2016, is coming up in November (Lund, Sweden). We plan for on-site participation although with online backup.

Wishing you all a good and well deserved summer!

Best regards, Lars A. Akslen, Director

Programs and Research Teams

Mechanisms of Tumor-Microenvironment Interactions:

- Donald Gullberg
- Karl-Henning Kalland
- Emmet McCormack

Exploration and Validation of Cancer Biomarkers:

- Lars A. Akslen
- Jim Lorens
- Camilla Krakstad
- Daniela Costea
- Elisabeth Wik

Clinical Applications and Trial Studies:

- Bjørn Tore Gjertsen
- Oddbjørn Straume
- Line Bjørge

Health Ethics, Prioritization and Economics:

- Roger Strand
- John Cairns
- Ole Frithjof Norheim

Additional resources: Bioinformatics and Big Data

- Inge Jonassen

Strategic Advice

- Rolf Reed

Centre Director:

Prof. Dr. Med Lars A. Akslen
+ 47 55 97 31 82
lars.akslen@uib.no

Administrative Leader:

Geir Olav Løken
+ 47 55 58 54 36
geir.loken@uib.no

All administrative officers: [link.](#)

FIRST EVER FULLY DIGITAL CCBIO SYMPOSIUM

A broad range of renowned international cancer scientists gave talks at this year's CCBIO Annual Symposium, which for the very first time was held as a fully online event. 331 participants in an international mix were participating at the symposium May 19 and 20, having the option to hop in and out of the lectures of their choice.


The program was broadly composed and covered various fields and perspectives within cancer research.

"We had an exceptionally good program spanning two days, featuring «big guns» in several cancer research fields," says CCBIO Director Lars A. Akslen.

He thinks the fact that the meeting was entirely digital made it easier to secure top scientist names. Normally, the participants gather in idyllic surroundings at Solstrand Hotel outside of Bergen. Akslen hopes the research communities will be able to meet in person at Solstrand in the coming years, supplemented by live streaming.

As the usual poster presentations could not be possible this time, younger researchers were instead invited to hold short 3-minute presentations. The program accommodated for 16 young researchers both days, 32 altogether. After each day's presentations, the attendees voted for an Audience Award and the sessions chairs decided on the Chairs Award for best presentations. Congratulations to Luka Tandarić, Marta Espevold Hjelmeland, Katrin Kleinmanns and Karen Gissum, and their supervisors Line Bjørge, Emmet McCormack, Camilla Krakstad and Roger Strand!

Read the [full article here](#).



THE PINDBORG PRIZE 2021 TO DANA COSTEA

Dana Costea is this year's receiver of the Pindborg Prize, an annual award issued by The Scandinavian Fellowship of Oral Pathology and Oral Medicine (SFOPOM), in memory of the late Professor Jens J. Pindborg, internationally renowned dentist and pathologist.

The SFOPOM include members from the majority of the Scandinavian universities, and also from Finland, the Netherlands and Italy. The society has had annual meeting since 1977, and since 1985, an exceptional and significant researcher or consultant in oral pathology or oral medicine has been asked to give the Pindborg lecture, which is considered as a great honour.

The association highlights that Dana was one of the first to describe the heterogeneity of cancer associated fibroblasts in oral squamous cell carcinoma, and has established robust 3D organotypic models of normal and neoplastic human oral mucosa as research tools for tumor-stroma interactions.

In her Pindborg lecture June 24, 2021 at the 20th International Congress on Oral Pathology & Oral Medicine, a Joint Meeting of the IAOP and BSOMP with the Scandinavian Fellowship of Oral Pathology and Oral Medicine, Dana gave a talk on Multifaceted tumor-stroma interactions in oral squamous cell carcinoma.

[Read more here](#).

Pindborg Lecture
Multifaceted tumor-stroma (fibroblasts) interactions in oral squamous cell carcinoma



Professor Daniela-Elena Costea
DDS, PhD
Department of Clinical Medicine and
Centre for Cancer Biomarkers
University of Bergen, Norway


Joint meeting IAOP and BSOMP with SFOPOM
London 2021



Pindborg Lecture 2021
Scandinavian Fellowship for Oral Pathology and Oral Medicine

Outline

- Tumor microenvironment - fibroblasts
- When do fibroblasts become activated?
- Tumor-stroma (fibroblasts) interactions in oral squamous cell carcinoma
- Clinical significance and implications for research



THE IMPRESS STUDY IS NOW INITIATED

Blood samples from the first patient in Bergen to be included in the IMPRESS study has now been taken. This is a milestone in the work towards more personalized cancer treatment.

Line Bjørge heads the Bergen branch of the study, which is a joint national effort, actually the largest cancer study to be performed in Norway. All Norwegian hospitals with a cancer ward are participating. The aim is to use genetic analyses to identify patients who might benefit from off-label treatment; the use of drugs originally approved for a different kind of patient group. The patients will receive treatment custom designed for the detected genetic changes in the tumor. A drug approved for breast cancer patients with a specific genetic alteration, might in this context be used to treat patients with a different cancer, but with the same genetic alteration.

All patients in the IMPRESS study are offered a comprehensive gene-panel test mapping 500 genes. Testing with such a comprehensive panel has not previously been available in Norway. As a result of this study, this will be introduced in Norway through the public health services.

Read more here in an [article in Dagens Medisin](#), and a [Helse Bergen article](#) (both in Norwegian).



THE FACULTY DISSEMINATION AWARD TO OLE FRITHJOF NORHEIM, AND BCEPS TO COE FINALS

The Faculty of Medicine at the University of Bergen will this year be issuing the Dissemination Award to Ole Frithjof Norheim, Professor at the Department of Global Public Health and Primary Care, Associate Investigator at CCBIO, and director of BCEPS (Bergen Centre for Ethics and Priority Setting).

The committee consisted of heads of research at the faculty's five departments, in addition to the vice-dean. The award will be presented at the Faculty Day, which this year is postponed to the fall term. The committee among other highlights Norheim's unique ability to disseminate research-based knowledge to society's decision-makers, both nationally and internationally, for a better and more sustainable societal development. He contributes to a much heated debate with a voice characterized by objectivity, bringing clear advice and opinions based on solid research.

[Read more here](#) (in Norwegian).

Note also that BCEPS is one of seven applicants from the University of Bergen to reach the final round of the Research Council of Norway's Centre of Excellence (CoE) initiative. The proposed BCEPS Centre of Excellence will be led by the Director Ole Frithjof Norheim and Guri Rørtveit (Head of Department at the Department of Global Public Health and Primary Care). If successful, the new centre will build on BCEPS' current applied research in Universal Health Coverage decision support to become a global Centre of Excellence for Ethics and Priority Setting in Health, the importance of which has become all the clearer in the light of the Covid 19 pandemic. [Read more here](#).



Photo by Ingvild Festervoll Melien

FIRST MENTEE OF THE ESMI MENTORING PROGRAM


Katrin Kleinmanns has been accepted as the very first Mentee of ESMI's (European Society for Molecular Imaging) Mentoring Program "Advancing Careers of Early-Stage Imaging Scientists in Academia".

[The ESMI Mentoring Programme](#) is based on a self-organized one-to-one mentoring, accompanied by ESMI-organized actions involving the mentee-peer-group and certain workshops.

The Mentee receives primarily:

- Feedback on career planning in line with his/her plans
- Individual support and inspiration with respect to strategic development and effective realization of a scientific career
- Knowledge, contacts, and formal as well as informal rules of the game with respect to working in science
- Support with the contemplation of personal skills/competencies and strengths
- Analysis of current career and future perspectives
- Self-reflection and self-confidence
- Confidence in decision making processes
- Visibility and positioning in the scientific community
- Access to information and career-relevant networks

Congratulations to Katrin for this great opportunity!



RESEARCH COUNCIL FUNDING TO TWO CCBIO PROJECTS

The Research Council of Norway [announced](#) June 24 which projects which this year will be supported in the category Research projects. Among these are CCBIO PI Emmet McCormack and Associate PI Camilla Krakstad.

Emmet McCormack receives funding for the project "Animal Model for evaluation of Innovative immunotherapy DEsigns - (AMIDE)". Applied for: NOK 12 000 000.

Camilla Krakstad receives funding for the project "Deciphering Heterogeneity to provide treatment for metastatic Endometrial cancers". Applied for: NOK 10 983 000.

Congratulations to both! Nationally, 260 researchers will be supported, out of more than 2000 who submitted their proposals in February. Altogether, 2,7 billion NOK are allocated, and of this, 383 million NOK go to 34 UiB researchers.

[Read more here](#) (in Norwegian).



With funding from

**The Research
Council of Norway**

UIB-IDÉ FUNDING TO CCBIO AML PROJECT

Three out of four innovation projects selected to be supported from the University of Bergen's new program UiB-idé, comes from the Medical faculty, and one of them is a CCBIO project.

Emmet McCormack / Pascal Gelebart receives NOK 350 000 for the project "Development of innovative immunotherapy for Acute Myeloid Leukemia (AML)."

CAR-T-treatment for blood cancer is a new and effective immunotherapy, but has currently major adverse effects for the patient. The project "Development of innovative immunotherapy for" Acute Myeloid Leukemia (AML)" aims to reduce the adverse effects by developing new CAR-T-cells that attack a certain cancer-specific antigen only, with no impact on the healthy cells. The McCormack group will use the UiB-idé funding to develop a CAR-T-cell system and utilize a mouse model to demonstrate its ability to kill cancer cells while saving the healthy cells.

The group is the first to incorporate this new cancer cell-specific antigen, which they discovered through their own research. The invention could potentially be of great importance for future CAR-T-cancer therapy, leading to reduced risk or better prognosis. The project is recommended by the committee partly due to its potentially groundbreaking approach and great societal value.

The application deadline for UiB-idé 2022 will be [announced here](#).

Read more about the [four supported projects](#) (in Norwegian only).



SUCCESSFUL DIGITAL COMPLETION OF BMED904

BMED904, the Graduate Course in Extracellular Matrix, was this year run jointly with the DIKU Summer School in Fibrosis, June 7-11. This was the first time the course was held through a digital platform, a bit of a challenge as parts of the course are lab based.

CCBIO PI Donald Gullberg is academic responsible for the course together with Professor Marion Kusche Gullberg, assisted by group members Mona Grønning and Ning Lu. 19 students were registered for ECTS participation, while 35 non-ECTS participants joined for professional updates. One of the lectures was also highlighted as a CCBIO Seminar with speaker Andrew Leask, attracting around 50 participants. All in all, people joined from different parts of Norway, and from Sweden, Denmark, Finland, UK, USA and Canada. See the [complete program here](#).

"We are by now used to digital meetings and conferences," Donald Gullberg says. "It was nevertheless new to us to include practical lab training in a digital format," he continues. This was solved by filming the lab work, and cells were also sent to a collaborative group in Canada, who filmed the microscopy work.

18 international speakers from Scandinavia, UK and North-America contributed. Donald Gullberg was surprised that so many were willing to do their talk live, not to miss out on the questions from the audience. One of the speakers even joined live from San Francisco at 4 in the morning.

Gullberg finds it important to facilitate contact between academia and the corporate world. "In 2019, we hosted a DIKU financed conference on fibrosis in Bergen, and noted an interest from several enterprises. We then included speakers from biotech companies in Europe and Australia," he says. "This year, we included a startup company in Toronto (Ronen Schuster, [Phenomic](#), and a listed company in San Francisco with an interest in integrins in fibrosis (Martin Decaris, [Pliant Therapeutics](#))," Gullberg explains.

The next BMED904 is planned for the spring term 2023.



Due credit to the behind-the-scenes heroes Torsteir Ravnskog and Margarethe Bittins (below) for administering the Zoom links, connections and testing.



SAVE THE DATE FOR THE SCANDINAVIAN SEMINAR ON TRANSLATIONAL PATHOLOGY 2021

We are happy to inform you of the tentative dates for the Scandinavian Seminar on Translational Pathology 2021, November 18-20, in Halmstad, Sweden, organized by Lund University. We plan for on-site participation, but will monitor the pandemic closely and adapt to a digital platform if needed.

SCANPATH is an annual network meeting for Scandinavian tumor pathologists and pre-clinical scientists with an interest in the prospects of next generation tissue profiling. The aim is to stimulate tissue-based studies of tumor mechanisms and biomarker mapping. This initiative has been a success since the startup in 2016, and SCANPATH is now a well established annual forum.

Similar to previous years, the seminar will include inspirational speakers representing the different research groups attending the meeting.

We will have one poster session where participants can present their work, and ample time for informal interaction. The seminar is open for all with an interest in morphology oriented research, so please feel free to circulate this invitation to relevant partners and collaborators.

Details will follow.

Please let Lars A. Akslen know if you would like to give a talk or present a poster.

Registration: will be available [on the website](#). Save the date November 18-20!



Illustration: From Halmstad, colourbox.com

CONFERENCE IN PEDIATRIC CANCER RESEARCH AND PRECISION MEDICINE IN NORWAY

Haukeland University Hospital and UiB, involving Bjørn Tore Gjertsen and Emmet McCormack, in collaboration with the Norwegian Childhood Cancer Society, organize the conference Precision medicine in childhood cancer September 23-24, 2021, in Bergen. Registration is open.

The meeting is on-site in Bergen, with two international keynote speakers and discussions facilitating national and international collaboration in the pediatric cancer field. The target audience is pediatric oncologists and people in the pediatric oncology field, as well as researchers in clinical and preclinical pediatric oncology, working *in vitro* or with animal models.

When: September 23-24, 2021

Where: Auditorium Bikuben, Haukeland University Hospital, Bergen, Norway

Program: [On this link](#)

Registration: Please use [this form](#)

Welcome!



DEADLINE FOR THE FALL TERM COURSES IS SEPT. 1

From **July 1**, it is possible to register for the fall term courses from CCBIO and Neuro-SysMed, and deadline is **September 1**.

For all courses, please register in [Studentweb](#) if you are already enrolled at the UiB. If you are *not* enrolled at the UiB, you register through [Søknadsweb](#), where you simultaneously apply for UiB guest student status. We now aim for a term with on-site participation for all courses, on campus Haukeland University Hospital. Note that only the Clinical Trials course (CCBIONEUR911) accept non-ECTS participation, and the course on Patient and Public Involvement in Medical and Health Research (CCBIONEUR910) accepts non-ECTS participation for patient/user representatives only.

Find your course(s) below. Supervisors: please advise your students to check these out.

CCBIO903 – CANCER RESEARCH: ETHICAL, ECONOMIC AND SOCIAL ASPECTS

CCBIO903 is a unique 5 ECTS course which focuses on ethical, economical and societal aspects of cancer and cancer research and aims to equip PhD candidates with tools for systematic reflection on their own and related research as well as methods for assessing the cost benefit of health measures and methods of treatment.

The course will address difficult questions:

- How can we deal with the uncertainties in the lab, while maintaining the quality of our science?
- Which drug is more suited to a patient?
- How can medical science contribute to debates on what is good for society?
- How can economic models help guide health care resource allocation?

When: Course week 1: September 6-10, 2021, and course week 2: October 11-14, 2021. Location will be announced (on-site, at the Haukeland University Hospital campus).

[John Cairns](#), [Roger Strand](#) and [Anne Blanchard Bremer](#) are academic responsible for the course. Administrative coordinator is [Kjetil Utvik Harkstad](#).

More info: at the [website](#) and [the student pages](#).




Illustration: Lightspring

CCBIONEUR911 – CLINICAL TRIALS

The completed program qualifies for a Good Clinical Practice (GCP) certificate and covers several aspects of clinical trials – from design planning to execution – with learning examples from cancer research and neurological research alike. Open to all.

[Line Bjørge](#), CCBIO and [Øivind Grytten Torkildsen](#), Neuro-SysMed are academically responsible. Administrative coordinators are [Benedicte Sjo Tislevoll](#), CCBIO and [Hilde Norborg](#), Neuro-SysMed.

Topics lectured:

- Study design
- The pharmaceutical company perspective
- The patient's perspective
- Ethics
- GCP overview and concepts
- Practical running of a clinical trial
- Formalities and regulations
- Writing a protocol
- Applications and funding
- Contracts
- Translational research protocols
- Clinical trials as part of normal clinical operations
- Success factors
- Clinical trials in the future

When: September 29 – October 1, 2021

Where: On-site, campus Haukeland University Hospital, Bergen.

Registration: [Studentweb/Søknadsweb](#) (see page 5) for ECTS participation, deadline Sept. 1. Non-ECTS participation: [use this link](#).

ECTS: 2 ECTS. **More info:** at the [website](#) and the [student pages](#).



Illustration: colourbox.com

CCBIONEUR910: PATIENT AND PUBLIC INVOLVEMENT IN MEDICAL AND HEALTH RESEARCH

The course aims to inspire increased user participation in research trials and will present methods on how to involve user representatives. This is highly relevant to all biomedical research fields, and Patient and Public Involvement is documented to positively impact the relevance and efficacy in medical research. The main objective of the course is to develop the participants' capacity to assess and convey the value of patient and public involvement in general, as well as promoting productive user involvement in their own research projects.

[Nina Jebsen](#), CCBIO, [Kjell-Morten Myhr](#), Neuro-SysMed and [Tone Skår](#), Neuro-SysMed and VIS are academic responsible. Coordinators are [Pål Tore Bentsen](#), CCBIO and [Hilde Norborg](#), Neuro-SysMed.

The primary language will be Norwegian for this course.

When: November 3-5, 2021

Where: On-site, campus Haukeland University Hospital, Bergen.

Registration: [Studentweb/Søknadsweb](#) (see page 5) for ECTS participation, deadline Sept. 1. Non-ECTS participation for user repr.

ECTS: 2 ECTS.

More info: at the [website](#) and the [student pages](#).



Illustration: colourbox.com

CCBIONEUR912: HEALTH INNOVATION

The course aims to teach PhD candidates and other researchers how to recognize the close connection between research findings and innovation potential. The course will use examples to showcase the practical route from idea to patent – and beyond. Professional expertise will provide good understanding of the legal and practical framework for research-based innovation, including how to protect and exploit intellectual property. The students will also be introduced to the perspective of early stage venture capital fund managers and learn about the available funding instruments for the various stages of development.

Academic responsible are [Agnete Engelsen](#), CCBIO and [Nina Grytten Torkildsen](#) and [Magnus Alvestad](#), Neuro-SysMed. Administrative coordinators are [Ning Lu](#), CCBIO and [Hilde Norborg](#), Neuro-SysMed.

When: November 8-9 and December 2-3, 2021

Where: On-site, campus Haukeland University Hospital, Bergen.

Registration: [Studentweb/Søknadsweb](#) (see p. 5), deadline Sept. 1.

ECTS: 4 ECTS.

More info: at the [website](#) and the [student pages](#).



Illustration: colourbox.com

RELEVANT CALLS FOR FUNDING

Here is a list of current and relevant calls, so take a look and see if any of these are relevant for you.

European Research Council:

- Advanced grant, deadline August 31, 2021
- Starting grant, January 13, 2022
- Consolidator grant, March 17, 2022
- Advanced grant, April 28, 2022
- Synergy grant, November 10, 2022

Marie Skłodowska-Curie Actions:

- **European Postdoctoral Fellowships:** Fellows (any nationality) either come to Europe from any country in the world or move within Europe for a project. The standard duration of these fellowships must be between 12 and 24 months.
- **Global Postdoctoral Fellowships:** European nationals or long-term residents who wish to engage in projects with organisations outside EU Member States and Horizon Europe Associated Countries. These fellowships require an outgoing phase of minimum 12 and maximum 24 months in a non-associated Third Country, and a mandatory 12-month return phase to a host organisation based in an EU Member State or a Horizon Europe Associated Country. More information: UiB MSCA Fact sheet ([PDF](#)). Deadline 15 September 2021

Horizon Europe—Health Cluster

Research and Innovation actions (RIA) and Coordination and support actions (CSA) that address specific global societal challenges. Detailed information on these calls (and many more) is found in the latest draft of the [Work Programme, v.7 \(PDF\)](#) Contact person at UiB: katie.anders@uib.no

Research– and innovation actions:

- Next generation advanced therapies to treat prevalent and high burden diseases with unmet needs, HORIZON-HLTH-2021-TOOL-06-02. Deadline 21.09.21
- Clinical validation of Artificial Intelligence solutions for treatment and care, HORIZON-HLTH-2021-DISEASE-04-04. Deadline 21.09.21
- Innovative tools for use and re-use of health data (in particular electronic health records and/or patient registries), HORIZON-HLTH-2021-TOOL-06-03 Deadline 21.09.21
- Pre-clinical development of the next generation immunotherapies for diseases or disorders with unmet medical need, HORIZON-HLTH-2022-DISEASE-06-02 Deadline 01.02.22
- Development of new effective therapies for rare diseases, HORIZON-HLTH-2022- DISEASE-06-04. Deadline 01.02.22
- Trustworthy AI tools to predict the risk for chronic non-communicable diseases and/or their progression, HORIZON-HLTH-2022-STAYHLTH-01-04 Deadline 01.02.22
- Non-communicable diseases risk reduction in adolescence and youth, HORIZONHLTH-2022-DISEASE-07-03 Deadline 21.04.22
- Computational models for new patient stratification strategies, HORIZON-HLTH2022-TOOL-12-01 Deadline 21.04.22

Coordination- and support actions:

- A roadmap for personalized prevention, HORIZON-HLTH-2021-STAYHLTH-01-04. Deadline 21.09.21
- Development, procurement and responsible management of new antimicrobials, HORIZON-HLTH-2021-IND-07-02 Deadline 21.09.21

DAM stiftelse:

- [Helse](#), Sept 15, 2021

Merck 2021 Research Grants, deadline August 31, 2021.

- Drug Discovery - 3 grants comprising 350,000 €/year for 3 years with the option of extension.
- Real time testing and sensors - grant comprising between 100,000 - 500,000 \$/year for 2 years with the option of extension
- Nanoparticle for nucleic acid delivery - grant comprising between 100,000 - 300,000 \$/year for 2 years with the option of extension
- Digital Innovation - 3 grants comprising 40,000 - 100,000 € for 1 year with the option of extension
- Bioelectronics - grant comprising 150,000 €/year for 3 years
- Sustainability - grant/s to be negotiated on a case by case basis
- Media recycling for cultured meat - grant/s to be negotiated on a case by case basis
- Organoids - grant/s to be negotiated on a case by case basis

Nordic Cancer Union, funding to support and stimulate collaborative cancer research within the Nordic countries. Deadline: 1 September 2021.

Olav Thon Foundation, [award for excellent teaching in natural sciences and medicine](#). Deadline September 15, 2021.


Travel grants: [Research Council of Norway](#), continuing deadline. [Helse Vest](#), continuing deadline.

[ERASMUS](#): UiB staff including PhD-candidates and post docs, to attend courses or individual laboratory visits, deadline: 20 August and 20 January.



COMING CCBIO EVENTS

Make sure to save the dates in your calendar, and register when applicable. You can see all planned CCBIO events in the [CCBIO web calendar](#).



- CCBIO Seminars for the fall term, tentative dates: August 26, September 30, October 28, November 25, December 16
- September 6-10 + October 11-14, [CCBIO903 – Cancer research: Ethical, economic and social aspects](#), on campus
- September 9–October 1, [CCBIONEUR911: Clinical Trials course](#), on campus
- September 23-24, [Pediatric cancer research and precision medicine in Norway](#), Auditorium Bikuben, Haukeland University Hospital, Bergen
- November 3-5, [CCBIONEUR910: Patient and Public Involvement in Medical and Health Research](#) course, on campus (primarily in Norwegian)
- November 8-9 and December 2-3, [CCBIONEUR912: Health Innovation](#) course, on campus.
- November 18-20, [the Scandinavian Seminar on Translational Pathology 2021](#), in Halmstad, Sweden. We plan for on-site participation, but will monitor the pandemic closely and adapt to a digital platform if needed. Registration: not yet open, **save the date!**

OTHER COMING EVENTS



- July 5, [Horizon Europe Brokerage Event](#), get all information needed on the upcoming Horizon Europe calls in the Cluster Health Work Programme, and meet potential partners from Europe and beyond and start building your consortium. Registration until June 30. Online event.
- August 18, Arendalsuka 2021: [Fremtidens kreftbehandling og helsedata – fra politikk til klinikk](#), Oslo Cancer Cluster, Kreftforeningen, Legemiddelindustrien, Janssen Norge, MSD Norge, AstraZeneca Norge
See also Arendalsuka 2021: [Hvordan sikre morgendagens helsetjeneste med nok testkapasitet i Norge](#), and [Arendalsuka 2021: Hvordan lykkes vi med presisjonsmedisin for kreft? – Forskning og samarbeid som tar oss videre](#).
- August 30–September 3, [Biotechgate Digital Partnering 2021](#). Five-day international conference which will take place virtually and is free to attend.
- October 5-6, [Goodbye Flat Biology: Next Generation Cancer Models](#), virtual event. European Association for Cancer Research (EACR) conferences. Abstract submission deadline: 17 August 2021, Registration deadline: 14 September 2021.
- October 26-27, [AI in Cancer Diagnostics: from research to clinical practice](#), virtual event. European Association for Cancer Research (EACR) conferences. Abstract submission deadline: 6 September 2021, Registration deadline: 20 September 2021.
- November 10-12, [Digital Life 2021](#). Main conference day November 11, with associated events November 10 and 12. The annual conference for the Centre for Digital Life Norway. Venue: in Oslo.
- November 15-18, [Medica 2021 – World Medicine Forum](#), Düsseldorf, Germany.

PUBLICATIONS

You can find the CCBIO publications [on this pubmed link](#) (link shortened through Tinyurl). See the most recent 5 below.



Zhang J, Terán G, Popa M, Madapura H, Ladds MJGW, Lianoudaki D, Grünler J, Arsenian-Henriksson M, McCormack E, Rottenberg ME, Catrina SB, Láin S, Darekar S. [DHODH inhibition modulates glucose metabolism and circulating GDF15, and improves metabolic balance](#). iScience. 2021 May 1;24(5):102494. doi: 10.1016/j.isci.2021.102494. eCollection 2021 May 21.

Hellesøy M, Engen C, Grob T, Löwenberg B, Valk PJM, Gjertsen BT. [Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis](#). Mol Oncol. 2021 Jun 8. doi: 10.1002/1878-0261.13035. Online ahead of print.

Chen Y, Klingen TA, Aas H, Wik E, Akslen LA. [Tumor-associated lymphocytes and macrophages are related to stromal elastosis and vascular invasion in breast cancer](#). J Pathol Clin Res. 2021 Jun 2. doi: 10.1002/cjp2.226. Online ahead of print.

Mohamed N, van de Goor R, El-Sheikh M, Elrayah O, Osman T, Nginamau ES, Johannessen AC, Suleiman A, Costea DE, Kross KW. [Feasibility of a Portable Electronic Nose for Detection of Oral Squamous Cell Carcinoma in Sudan](#). Healthcare (Basel). 2021 May 3;9(5):534. doi: 10.3390/healthcare9050534.

Ngai LL, Ma CY, Maguire O, Do AD, Robert A, Logan AC, Griffiths EA, Nemeth MJ, Green C, Pourmohamad T, van Kuijk BJ, Snel AN, Kwidama ZW, Venniker-Punt B, Cooper J, Manz MG, Gjertsen BT, Smit L, Ossenkoppele GJ, Janssen JJWM, Cloos J, Sumiyoshi T. [Bimodal expression of potential drug target CLL-1 \(CLEC12A\) on CD34+ blasts of AML patients](#). Eur J Haematol. 2021 May 30. doi: 10.1111/ejh.13672. Online ahead of print.

RECENT CCBIO IN THE MEDIA

Recent media appearances by CCBIO PIs and group members. For all media hits, see [CCBIO's web pages](#).



18.06.21, Dagens Medisin, "[Post-ASCO: Siste nytt innen gynkreft](#)", Line Bjørge.

11.06.21, UiB Aktuelt, "[Syv SFF-finalister fra UiB](#)", Ole Frithjof Norheim/BCEPS.

08.06.21, HealthTalk, "[Utfordrer Imbruvica: Calquence med færre kardiovaskulære bivirkninger](#)", Bjørn Tore Gjertsen.

04.06.21, HealthTalk, "[Tror kombinasjonen Venclyxto og azacitidin blir standardbehandling for pasienter som ikke kan motta intensiv cellegift](#)", Bjørn Tore Gjertsen.

20.05.21, På Høyden, "[Milliondryss til innovasjoner ved UiB](#)", Emmet McCormack. 19.05.21, Dagens Medisin, "[Stoppet studie viser effekt av immunterapi for livmorhalskreft-pasienter](#)", Line Bjørge.

05.05.21, HealthTalk, "[Norske forskere har oppdaget en genmarkør med sterk prognostisk effekt ved brystkreft](#)", Lars A. Akslen, Elisabeth Wik, Lise Ingebriktsen.

28.04.21, På Høyden, "[Karikerer kreftcellen](#)", Henriette Ertsås.

18.04.21, Nord24, "[- Enten blir det suksess, eller så blir det fiasko](#)", Nina Louise Jebsen (Gjertsen group).

16.04.21, Gynkreftforeningen, Afrodite magazine, "[Ny studie på platinumresistent eggstokkreft](#)", Line Bjørge.

13.04.21, Romsdals Budstikke, "Talentstipend til Hanna (22) og to andre romsdalinger", Hanna Kosberg Bredin (Krakstad group).

